Neurocrine Biosciences (NASDAQ:NBIX) Stock: Insider George Morrow Sells 7,200 Shares

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director George Morrow sold 7,200 shares of the business’s stock in a transaction that occurred on Tuesday, November 3rd. The stock was sold at an average price of $166.37, for a total value of $1,197,864.00. Following the transaction, the director owned 10,386 shares in the company, valued at approximately $1,727,918.82. This represents a 40.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Neurocrine Biosciences Stock Performance

NASDAQ:NBIX opened at $166.05 on Thursday. Neurocrine Biosciences, Inc. has a one year low of $122.14 and a one year high of $186.12. The stock has a market cap of $16.81 billion, a PE ratio of 24.64, a P/E/G ratio of 0.73 and a beta of 0.36. The stock has a 50 day moving average price of $146.98 and a 200 day moving average price of $147.77.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Monday, November 2nd. The company reported $3.29 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $1.38. Neurocrine Biosciences had a return on equity of 23.39% and a net margin of 18.98%. The firm had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter last year, the business posted $2.04 earnings per share. The firm’s revenue was up 41.3% compared to the same quarter last year. As a group, analysts predict that Neurocrine Biosciences, Inc. will post 7.66 earnings per share for the current fiscal year.

Key Stories Impacting Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Neurocrine reported Q3 revenue of $1.12 billion, up 41% year over year and above expectations, with EPS of $3.29 also beating estimates. The company raised its 2026 INGREZZA sales outlook to $2.9–$2.925 billion, reflecting product demand and supporting the growth outlook. Q3 results and updated sales outlook
• Positive Sentiment: Guggenheim raised its price target to $224 from $207 and maintained a Buy rating. Canaccord, Piper Sandler and RBC also lifted their targets after the results, adding to a broadly favorable analyst response.
• Neutral Sentiment: The company has started a Phase 2 Alzheimer’s study, offering a potential longer-term pipeline opportunity, but the supplied report provides few details on the study or its prospects. Alzheimer’s study update
• Negative Sentiment: Director George J. Morrow reported selling shares in multiple transactions, including sales on November 2 and 3. The filings indicate the trades were made under a pre-arranged Rule 10b5-1 plan, which may lessen the significance, but insider selling can still concern investors.
• Negative Sentiment: A report flagged potential integration challenges and legacy liabilities related to Neurocrine’s Soleno acquisition, which could affect how much value the company ultimately captures from the deal. Soleno acquisition risks

Wall Street Analyst Weigh In

A number of analysts have issued reports on NBIX shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $204.00 target price on shares of Neurocrine Biosciences in a research note on Friday, October 16th. Morgan Stanley boosted their price target on shares of Neurocrine Biosciences from $183.00 to $185.00 and gave the company an “equal weight” rating in a research report on Tuesday. UBS Group lowered their price target on shares of Neurocrine Biosciences from $231.00 to $214.00 and set a “buy” rating on the stock in a research report on Tuesday, September 29th. Mizuho raised shares of Neurocrine Biosciences to a “hold” rating in a report on Wednesday, September 16th. Finally, Zacks Research cut shares of Neurocrine Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 4th. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $202.32.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Bank of America Corp DE boosted its stake in Neurocrine Biosciences by 10.6% during the first quarter. Bank of America Corp DE now owns 583,827 shares of the company’s stock worth $76,913,000 after buying an additional 55,723 shares during the period. ABN AMRO Bank N.V. purchased a new stake in shares of Neurocrine Biosciences in the 2nd quarter valued at approximately $2,510,000. Focus Partners Advisor Solutions LLC purchased a new stake in shares of Neurocrine Biosciences in the 2nd quarter valued at approximately $1,927,000. Engineers Gate Manager LP lifted its holdings in shares of Neurocrine Biosciences by 64.0% in the 2nd quarter. Engineers Gate Manager LP now owns 18,361 shares of the company’s stock worth $3,094,000 after acquiring an additional 7,163 shares during the last quarter. Finally, SEB Asset Management AB purchased a new position in shares of Neurocrine Biosciences during the 1st quarter worth approximately $10,483,000. 92.59% of the stock is currently owned by institutional investors and hedge funds.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company’s research programs target conditions in which treatments may address significant unmet medical needs.

Neurocrine’s leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease.